BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials

Reuters01-05

Jan 5 (Reuters) - Genelux Corp GNLX.O:

GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALS
GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE COHORT & OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)
GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026

Source text: ID:nGNXbV0bkb

Further company coverage: GNLX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601882369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601882369","market":"nz","top_or_hot":-1,"title":"BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials</title></head><body><p><span>Jan 5 (Reuters)</span><span> - </span>Genelux Corp <span>GNLX.O</span>:</p><ul><li><p>GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALS</p></li><li><p>GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> &amp; OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)</p></li><li><p>GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNXbV0bkb</span></p><p>Further company coverage: <span>GNLX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials</title></head><body><p><span>Jan 5 (Reuters)</span><span> - </span>Genelux Corp <span>GNLX.O</span>:</p><ul><li><p>GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALS</p></li><li><p>GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> &amp; OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)</p></li><li><p>GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNXbV0bkb</span></p><p>Further company coverage: <span>GNLX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GNLX","symbol_name":"Genelux Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60FA:1","article_id":"2601882369","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601882369","pubTimestamp":1767621671,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer TrialsJan 5 (Reuters) - Genelux Corp GNLX.O:GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALSGENELUX- IN AD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GNLX":"Genelux Corporation","BK4139":"生物科技"},"translate_title":"简介-Genelux Corp公布正在进行的肺癌试验的中期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNLX":0.9},"content_text":"BRIEF-Genelux Corp Announces Interim Results From Ongoing Lung Cancer TrialsJan 5 (Reuters) - Genelux Corp GNLX.O:GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALSGENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE COHORT & OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026Source text: ID:nGNXbV0bkbFurther company coverage: GNLX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601882369","isCrawlerRequest":true}